Form 4 for TNYA Tenaya Therapeutics, Inc.
Accepted 2026-08-17 20:49:28 ET · period of report 2026-08-17 · accession 0001193125-26-354517 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-08-17 20:49 | 2026-08-17 | TNYA | Tingley Whittemore | Chief Medical Off | S - Sale | $0.7098 | -7,424 | 214.1K | -3% | -$5,270 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | S | D | 1,637 | $0.7098 | 219,860 | D | — | — | (F1) Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. (F2) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F3) Includes 108,544 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 6,000 shares of common stock acquired pursuant to the Tenaya Therapeutics, Inc. 2021 Employee Stock Purchase Plan on June 10, 2026. |
| 2 | Common | Common Stock | 2026-08-17 | S | D | 1,637 | $0.7098 | 218,223 | D | — | — | (F4) Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. (F2) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F5) Includes 104,169 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| 3 | Common | Common Stock | 2026-08-17 | S | D | 1,871 | $0.7098 | 216,352 | D | — | — | (F6) Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025. (F2) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F7) Includes 99,169 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| 4 | Common | Common Stock | 2026-08-17 | S | D | 2,279 | $0.7098 | 214,073 | D | — | — | (F8) Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 3, 2026. (F2) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F9) Includes 93,076 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |